News

FDA calls for reforms to bridge the gap between bench and bedside

BMJ 2010; 341 doi: http://dx.doi.org/10.1136/bmj.c5611 (Published 08 October 2010) Cite this as: BMJ 2010;341:c5611
  1. Bob Roehr
  1. 1Washington DC

The head of the US Food and Drug Administration has called for major reforms in the regulation and approval of new medicines to help bridge the gap between the advances being made in basic science and patient care.

Margaret Hamburg, director of the agency, was speaking at the National Press Club in Washington DC on 6 October at the launch of a white paper that provides a framework for such reform.

In 2008 the private sector invested $80bn (£50.6bn; €58.2bn) in biomedical research and the US National Institutes of Health another $30bn. Discoveries in fields such as genomics, biologics, …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe